Trial Profile
A Single- and Multiple Ascending-Dose, Randomized, Double-Blind, Placebo-Controlled Study in Two Single-Center Study Parts to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5285119 Following Oral Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Balovaptan (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
- Sponsors Roche
- 01 Aug 2021 Results of the early-phase pharmacokinetics from pooled data of two phase I studies ( NCT03764449 and NCT01418963) published in the Expert Opinion on Investigational Drugs
- 23 May 2013 Actual end date changed from Oct 2012 to Jul 2012 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.